+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - a randomized controlled, cross-over trial

Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis - a randomized controlled, cross-over trial

Alimentary Pharmacology and Therapeutics 26(9): 1259-1265

BackgroundGastro-oesophageal reflux disease (GERD) is an important problem in systemic sclerosis due to impaired salivation and oesophageal function.AimTo determine the efficacy of adding ranitidine at bedtime to control nocturnal acid breakthrough (NAB) and GERD in patients with systemic sclerosis already prescribed high-dose omeprazole.MethodsPatients with systemic sclerosis and GERD symptoms (n = 14) were treated with omeprazole 20 mg b.d. and either placebo or ranitidine 300 mg at bedtime for 6 weeks in a randomized, cross-over, placebo controlled study. At the end of each period a 24 h pH-study with intragastric and oesophageal pH measurement was performed.ResultsPathological acid reflux occurred in eight patients with omeprazole/placebo and in seven with omeprazole/ranitidine (P = ns) with technically adequate oesophageal pH-studies (n = 13). NAB was present in eight patients with omeprazole/placebo and six with omeprazole/ranitidine (P = ns) in whom technically adequate gastric pH-studies were obtained (n = 10). The addition of ranitidine had no consistent effect on patient symptoms or quality of life.ConclusionMany patients with systemic sclerosis experienced NAB and pathological oesophageal acid exposure despite high-dose acid suppression with omeprazole b.d. Adding ranitidine at bedtime did not improve NAB, GERD or quality of life in this population.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 020732446

Download citation: RISBibTeXText

PMID: 17944740

DOI: 10.1111/j.1365-2036.2007.03469.x

Related references

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology 115(6): 1335-1339, 1998

Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology 56(2): 214-222, 2016

Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Digestive Diseases and Sciences 50(3): 443-448, 2005

Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium. Gastroenterologie Clinique et Biologique 13(5): 457-462, 1989

Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-A prospective, controlled trial. Alimentary Pharmacology & Therapeutics 13(6): 819-826, 1999

Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Diseases of the Esophagus 25(5): 373-380, 2012

Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial. Clinical and Experimental Gastroenterology Volume 12: 337-347, 2019

Mo1077 Randomized Controlled Trial of Efficacy of Mosapride Plus Omeprazole Versus Omeprazole Alone in Therapy of Gastroesophageal Reflux Disease. Gastroenterology 142(5): S-589, 2012

Does baclofen decrease acid reflux and clinical symptoms in patients with gastroesophageal reflux disease? A prospective, randomized, double-blinded, placebo-controlled Trial. American Journal of Gastroenterology 98(9 Supplement): S35-S36, 2003

Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. Journal of Digestive Diseases 15(9): 469-476, 2015

Effects of combined enalapril and folic acid therapy on the serum uric acid levels in hypertensive patients: a multicenter, randomized, double-blind, parallel-controlled clinical trial. Internal Medicine 54(1): 17-24, 2015

The effect of bedtime ranitidine on the symptoms of nocturnal acid breakthrough in patients with refractory gastroesophageal reflux disease. American Journal of Gastroenterology 95(9): 2418, 2000

A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. Lasers in Surgery and Medicine 49(8): 738-742, 2017

Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: A randomized, controlled trial in Vietnamese patients with duodenal ulcer. Alimentary Pharmacology & Therapeutics 14(1): 97-101, 2000

Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients. Digestive Diseases 27(1): 68-73, 2009